Roche Holding AG
XETRA:RHO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
Roche Holding AG
XETRA:RHO
|
CH |
|
N
|
Norfolk Southern Corp
DUS:NFS
|
US |
Intrinsic Value
The intrinsic value of 
Roche Holding AG (RHO) under the Base Case is 214.79 EUR per share.
Compared with the current market price of 250 EUR, the stock appears
Overvalued by 14% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Roche Does
Roche Holding AG is a Swiss healthcare company that makes prescription medicines and diagnostic tests. Its drug business focuses on treatments in cancer, immunology, ophthalmology, and other serious diseases, while its diagnostics business sells instruments, lab tests, and software that help hospitals and laboratories detect disease and monitor patients. In simple terms, Roche helps doctors find illnesses and choose treatments, and it earns money by selling these medicines, test kits, and related systems to healthcare providers and distributors.
- Headquarters
- Switzerland CH
- Employees
- 100 920
- IPO date
- May 4, 2001
Roche Holding has no economic moat
Roche’s patents protect individual medicines for a time, but lower-priced copies and rival treatments can compete for customers when those protections end or another option is preferred. Patients and prescribers are not tied to Roche’s wider portfolio, and use of its medicines does not make them more valuable simply because more people use them; competitors can challenge Roche product by product.
Read the full moat analysis
Earnings Waterfall
Roche Holding AG
The intrinsic value for Roche Holding AG (RHO) under the Base Case is 214.79 EUR.
Compared with the current market price of 250 EUR, the stock appears Overvalued by 14% .